Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 01 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-0.98 Insider Own14.40% Shs Outstand173.07M Perf Week-12.71%
Market Cap728.81M Forward P/E- EPS next Y-0.87 Insider Trans0.00% Shs Float148.88M Perf Month42.03%
Income-158.16M PEG- EPS next Q-0.25 Inst Own63.44% Short Float / Ratio1.00% / 2.40 Perf Quarter25.45%
Sales5.52M P/S132.03 EPS this Y36.76% Inst Trans-2.98% Short Interest1.48M Perf Half Y44.48%
Book/sh1.04 P/B4.04 EPS next Y12.52% ROA-47.22% Target Price8.90 Perf Year58.71%
Cash/sh1.48 P/C2.84 EPS next 5Y- ROE-92.58% 52W Range1.60 - 4.83 Perf YTD120.53%
Dividend2.00 P/FCF- EPS past 5Y-26.10% ROI-69.53% 52W High-13.25% Beta1.68
Dividend %47.73% Quick Ratio8.16 Sales past 5Y208.44% Gross Margin- 52W Low161.87% ATR0.44
Employees399 Current Ratio8.16 Sales Q/Q-82.86% Oper. Margin-3085.55% RSI (14)56.25 Volatility19.64% 12.67%
OptionableYes Debt/Eq0.29 EPS Q/Q43.78% Profit Margin-2863.72% Rel Volume0.83 Prev Close4.28
ShortableYes LT Debt/Eq0.26 EarningsNov 02 BMO Payout- Avg Volume617.69K Price4.19
Recom1.44 SMA202.75% SMA5034.85% SMA20058.99% Volume512,868 Change-2.10%
Date Action Analyst Rating Change Price Target Change
Nov-09-23Initiated Deutsche Bank Buy $10
Mar-27-23Resumed Wells Fargo Overweight $8
Mar-17-23Initiated Bryan Garnier Buy $5
Jun-14-21Upgrade Jefferies Hold → Buy $6 → $12
Jan-29-21Downgrade JP Morgan Overweight → Neutral $9
Dec-28-20Resumed H.C. Wainwright Buy $19
Jul-31-20Initiated JP Morgan Overweight
Jul-22-20Initiated SunTrust Buy $38
Apr-22-20Initiated Mizuho Buy $18
Sep-23-19Initiated Needham Buy $26
Nov-27-23 07:00AM
Nov-15-23 07:00AM
Nov-06-23 07:00AM
Nov-05-23 05:34PM
Nov-02-23 09:00AM
07:11AM Loading…
Oct-17-23 07:00AM
Oct-11-23 08:07AM
Sep-05-23 07:00AM
Aug-07-23 04:32PM
Aug-04-23 06:29AM
Aug-03-23 07:00AM
Jul-19-23 07:00AM
Jul-18-23 07:00AM
07:00AM Loading…
Jul-06-23 07:00AM
Jun-27-23 07:00AM
Jun-20-23 07:00AM
Jun-16-23 07:00AM
Jun-14-23 09:39AM
Jun-06-23 07:00AM
Jun-04-23 07:11AM
Jun-02-23 07:00AM
May-22-23 07:00AM
May-12-23 07:00AM
May-04-23 07:00AM
May-01-23 10:15AM
Apr-27-23 07:01AM
Apr-26-23 04:01PM
07:06AM Loading…
Apr-25-23 07:00AM
Apr-20-23 07:00AM
Apr-16-23 09:30AM
Apr-14-23 11:08AM
Apr-04-23 07:00AM
Mar-14-23 07:00AM
Mar-13-23 07:00AM
Mar-08-23 10:45PM
Mar-07-23 07:00AM
Feb-28-23 09:40AM
Feb-15-23 07:00AM
Feb-08-23 11:05AM
Jan-24-23 09:40AM
Jan-23-23 05:49AM
Jan-20-23 07:00AM
Jan-09-23 07:00AM
Dec-26-22 12:35PM
Dec-21-22 04:01PM
Dec-12-22 10:00AM
Dec-09-22 11:31AM
Dec-08-22 09:11PM
Nov-30-22 07:00AM
Nov-29-22 11:35AM
Nov-09-22 05:16AM
Nov-05-22 08:35AM
Nov-03-22 09:31AM
Oct-21-22 07:00AM
Oct-12-22 11:30AM
Oct-04-22 10:21AM
Sep-20-22 07:30AM
Aug-04-22 07:00AM
Jul-21-22 07:54AM
Jul-11-22 06:00AM
Jul-06-22 07:00AM
Jun-10-22 03:01AM
May-31-22 04:01PM
May-27-22 07:45AM
May-13-22 06:58AM
May-12-22 10:51AM
May-05-22 07:00AM
May-02-22 04:31PM
Apr-25-22 07:01AM
Apr-02-22 03:11PM
Mar-31-22 07:00AM
Mar-29-22 07:00AM
Mar-10-22 07:00AM
Mar-03-22 07:00AM
Feb-21-22 07:00AM
Feb-01-22 04:15AM
Jan-19-22 10:00AM
Jan-10-22 07:01AM
Jan-05-22 07:00AM
Dec-13-21 07:00AM
Dec-06-21 07:00AM
Dec-03-21 04:53AM
Nov-15-21 07:00AM
Nov-10-21 07:00AM
Nov-08-21 09:29PM
Autolus Therapeutics Plc is a biopharmaceutical company, which engages in the development and commercialization of gene therapies. It uses proprietary and modular T cell programming technologies that are designed to recognize cancer cells, break down their defense mechanisms, and attack and kill these cells. The company was founded by Martin Pule in September 2014 and is headquartered in London, the United Kingdom.